Merck & Co., Inc. (MRK) is held by 21 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 8 funds adding and 7 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $8.6M sold). 1 member of Congress reported 2 purchases vs 1 sale. Latest close $137.78 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 12, 2026 · Congress to Nov 16, 2026.
Thornburg Investment Management · Kahn Brothers Group · DJE Kapital — 21 tracked funds hold MRK. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 1 sale ($8.6M). Insider trading 1 member of Congress reported buying (2 purchases vs 1 sale). Latest buy: Aug 19, 2026. Politician trading
PETROBRAS - PETROLEO BRASILEIRO SA (PBR) · ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · Arcos Dorados Holdings Inc. (ARCO) — stocks the same funds also hold. See all related stocks.
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +14.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
Tracked funds holding this stock, by quarter (2016Q3–2026Q2, 38 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.
| Institutions holding | 3,793 of 8,857 filers |
| Long-only filers among them | 3,779 |
| Change vs 2026 Q1 | +87 net · 2,118 entered · 2,031 exited |
| Shares reported, all filers | 1,958,782,160 |
| Reported value, all filers | $248.9B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $65.0B |
| Net income · FY2025 | $18.3B |
| Total assets · FY2025 | $136.9B |
| Shares outstanding | 2,467,171,638 |
| Market cap (at latest close) | $339.9B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 26,825,098 |
| Share of shares outstanding | 1.09% |
| Days to cover | 2.97 |
Shares short at recent settlements — Jul 31, 2026: 28.3M · Aug 14, 2026: 24.5M · Aug 31, 2026: 30.3M · Sep 15, 2026: 34.4M · Sep 30, 2026: 28.3M · Oct 15, 2026: 26.8M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 2K · Sep 15, 2026: 6K · Sep 30, 2026: 6K · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($8.6M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | 58,185 | $148.01 | $8.6M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | CHIRFI GUINDO | Officer | 10,000 | $1.4M | Aug 13, 2026 | SEC filing |
| Aug 12, 2026 | RICHARD ROBERT DELUCA JR | Officer | 11,699 | $1.5M | Aug 12, 2026 | SEC filing |
| Aug 12, 2026 | JENNIFER L ZACHARY | Officer | 80,315 | $10.7M | Aug 12, 2026 | SEC filing |
| Aug 11, 2026 | RICHARD ROBERT DELUCA JR | Officer | 12,837 | $1.7M | Aug 11, 2026 | SEC filing |
| Aug 10, 2026 | RICHARD ROBERT DELUCA JR | Officer | 20,784 | $2.7M | Aug 10, 2026 | SEC filing |
| Aug 6, 2026 | CHIRFI GUINDO | Officer | 15,000 | $2.0M | Aug 6, 2026 | SEC filing |
| Aug 6, 2026 | RICHARD ROBERT DELUCA JR | Officer | 6,050 | $788.8K | Aug 6, 2026 | SEC filing |
| Aug 5, 2026 | DAVID M WILLIAMS | Officer | 52,847 | $6.8M | Aug 5, 2026 | SEC filing |
| Aug 5, 2026 | DAVID MARALDO | Officer | 18,706 | $2.4M | Aug 5, 2026 | SEC filing |
| Feb 13, 2026 | CHIRFI GUINDO | Officer | 20,000 | $2.4M | Feb 9, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 186,323,766 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Mar 6, 2025 | The Vanguard Group | SC 13G/A | 253,257,639 | 10.0% | Feb 28, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (2 purchases vs 1 sale). Bought by Republicans. Latest buy: Aug 19, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Salazar, Maria Elvira | House | R | 2 | 1 | Sep 24, 2026 | $15,001 - $50,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 921 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (611), Medicare/Medicaid (553), Taxation/Internal Revenue Code (341).
Federal contracts: $2.5B in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $1.3B |
| FY2022 | $998.3M |
| FY2023 | $36.9M |
| FY2024 | $155.5M |
| FY2025 | $6.5M |
| FY2026 | $3.0M |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| W911QY21C0031 | Department of Defense | $2.2B | Jun 7, 2021 |
| HHSD200201458150C | Department of Health and Human Services | $1.5B | Apr 1, 2014 |
| HHSD200201793273C | Department of Health and Human Services | $1.5B | Apr 1, 2017 |
| HHSD200201354509C | Department of Health and Human Services | $1.4B | Apr 1, 2013 |
| HHSD200201250133C | Department of Health and Human Services | $1.4B | Apr 1, 2012 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Lynch PEG — Cheap against its growth rate
· Dividend Growth — Dividends raised for more than 10 years
· Neff Total Return Ratio — Growth plus dividends divided by P/E is high
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Growth — Latest revenue: $65.0B · 5-yr revenue CAGR: 9.4% · Straight growth years: 6
· Graham — Current ratio: 1.54 · Straight profitable years: 19 · Debt ratio: — · Latest net income: $18.3B
· Lynch PEG — P/E: 20.10 · 5-yr EPS growth: 21.2% · PEG: 0.95
· Dividend Growth — Dividend per share: 3.28 · Dividend yield: 2.2% · Straight dividend years: 19 · 10-yr dividend growth: 77.3%
· Neff Total Return Ratio — EPS growth: 21.2% · Dividend yield: 2.2% · P/E: 20.10 · Neff ratio: 1.17
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 12.60 · Operating cash flow: $16.5B · Net income: $18.3B
· Shareholder Yield — Shareholder yield: 3.6% · of which dividends: 2.2% · of which buybacks: 1.4%
· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 1 · Latest buy: Aug 19, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 38 of the last 40 quarterly lists; latest 2026 Q2, ranked #30 of 50.
· Politician BEST — appeared in 11 of the last 20 quarterly lists; latest 2025 Q3, ranked #45 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 10 | 50.0% | +4.8% | +2.1% | +2.7% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold MRK — ranked by lift, the co-holding pattern described in Methodology: PETROBRAS - PETROLEO BRASILEIRO SA (PBR) · ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · Arcos Dorados Holdings Inc. (ARCO) · BARCLAYS PLC (BCS) · EQUINOR ASA (EQNR) · ISHARES RUSSELL 1000 ETF (IWB).
Filings audit: every filing lens on Merck & Co., Inc. (MRK), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Nov 18, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 13, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
PETROBRAS - PETROLEO BRASILEIRO SA (PBR) · Filings audit: every filing lens on Merck & Co., Inc. (MRK), scored · Practice timing on MRK
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.